[敏感驱动基因阳性非小细胞肺癌软脑膜转移的药物治疗管理]
[Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer].
作者信息
Lu Zhiqin, Cai Jing, Zeng Zhimin, Liu Anwen
机构信息
Department of Oncology, The Second Affiliated of Nanchang University, Nanchang 330006, China.
Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang 330006, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):710-718. doi: 10.3779/j.issn.1009-3419.2020.102.18. Epub 2020 Aug 6.
Abstract
Leptomeningeal metastasis (LM) is one of the serious complications of advanced non-small cell lung cancer (NSCLC), although the incidence is not high, the clinical symptoms are severe and the prognosis is poor. LM is prone to occur in patients with positive driver gene than negative. At present, the treatment of LM mainly includes molecular targeted therapy, systemic chemotherapy, whole brain radiotherapy, intrathecal chemotherapy and immunotherapy. Although there are many treatments, the efficacy of LM is still unsatisfactory. This article reviews the drug therapy of sensitive driver gene positive NSCLC LM.
摘要
软脑膜转移（LM）是晚期非小细胞肺癌（NSCLC）的严重并发症之一，尽管其发病率不高，但临床症状严重且预后较差。与驱动基因阴性的患者相比，驱动基因阳性的患者更容易发生LM。目前，LM的治疗主要包括分子靶向治疗、全身化疗、全脑放疗、鞘内化疗和免疫治疗。尽管有多种治疗方法，但LM的疗效仍不尽人意。本文综述了敏感驱动基因阳性NSCLC-LM的药物治疗。
相似文献
1
[Management of Drug Therapy for Leptomeningeal Metastasis of Sensitive Driver Gene Positive Non-small Cell Lung Cancer].[敏感驱动基因阳性非小细胞肺癌软脑膜转移的药物治疗管理]
Zhongguo Fei Ai Za Zhi. 2020 Aug 20;23(8):710-718. doi: 10.3779/j.issn.1009-3419.2020.102.18. Epub 2020 Aug 6.
2
[Diagnosis and Treatment of Leptomeningeal Metastasis in Non-small Cell Lung Cancer].[非小细胞肺癌软脑膜转移的诊断与治疗]
Zhongguo Fei Ai Za Zhi. 2015 Oct 20;18(10):626-32. doi: 10.3779/j.issn.1009-3419.2015.10.05.
3
Leptomeningeal Metastases in Non-small Cell Lung Cancer: Optimal Systemic Management in NSCLC With and Without Driver Mutations.非小细胞肺癌中的脑膜转移：有无驱动基因突变的 NSCLC 的最佳全身治疗策略。
Curr Treat Options Oncol. 2020 Jul 28;21(9):72. doi: 10.1007/s11864-020-00759-3.
4
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.脑脊液游离 DNA 作为液体活检在 ALK 重排 NSCLC 脑膜转移中的临床应用
J Thorac Oncol. 2019 May;14(5):924-932. doi: 10.1016/j.jtho.2019.01.007. Epub 2019 Jan 17.
5
Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.表皮生长因子受体（EGFR）突变的非小细胞肺癌合并软脑膜转移患者的治疗与生存情况：一项回顾性队列分析
Lung Cancer. 2015 Sep;89(3):255-61. doi: 10.1016/j.lungcan.2015.05.023. Epub 2015 Jun 6.
6
[Epidermal growth factor tyrosine kinase inhibitors used in the treatment of NSCLC patients with leptomeningeal metastasis].用于治疗非小细胞肺癌软脑膜转移患者的表皮生长因子酪氨酸激酶抑制剂
Zhonghua Zhong Liu Za Zhi. 2016 Dec 23;38(12):920-924. doi: 10.3760/cma.j.issn.0253-3766.2016.12.008.
7
The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small-cell lung cancer-a retrospective study from one single cancer institute.非小细胞肺癌患者脑膜转移的临床特征和预后因素：一项来自单一癌症研究所的回顾性研究。
Cancer Med. 2019 Jun;8(6):2769-2776. doi: 10.1002/cam4.2156. Epub 2019 Apr 16.
8
[Use of Ommaya Reservoirs to Deliver Pemetrexed in Leptomeningeal Metastasis from Non-small Cell Lung Cancer: A Case Report and Review of the Literature].[使用奥马亚贮液器向非小细胞肺癌软脑膜转移患者递送培美曲塞：一例报告及文献复习]
Zhongguo Fei Ai Za Zhi. 2019 Aug 20;22(8):546-550. doi: 10.3779/j.issn.1009-3419.2019.08.12.
9
Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.培美曲塞治疗 EGFR 突变型肺癌患者的脑膜转移。
Clin Lung Cancer. 2019 Jul;20(4):e442-e451. doi: 10.1016/j.cllc.2019.03.005. Epub 2019 Mar 29.
10
Symptomatic leptomeningeal metastasis improvement with nivolumab in advanced non-small cell lung cancer patient.纳武单抗治疗晚期非小细胞肺癌患者症状性软脑膜转移的疗效改善
Lung Cancer. 2017 Jun;108:72-74. doi: 10.1016/j.lungcan.2017.02.022. Epub 2017 Feb 27.
引用本文的文献
1
Advances in the research of leptomeningeal metastases in non-small cell lung cancer: a narrative review.非小细胞肺癌软脑膜转移的研究进展：一篇叙述性综述
Transl Lung Cancer Res. 2025 Aug 31;14(8):3216-3232. doi: 10.21037/tlcr-2025-163. Epub 2025 Aug 26.
本文引用的文献
1
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）联合贝伐珠单抗治疗表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）伴多发脑转移患者，较 EGFR-TKIs 单药治疗有生存获益。
Eur J Cancer. 2019 Nov;121:98-108. doi: 10.1016/j.ejca.2019.08.021. Epub 2019 Sep 27.
2
A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer.一项关于鞘内注射培美曲塞治疗非小细胞肺癌难治性软脑膜转移的1期试点研究。
Front Oncol. 2019 Aug 30;9:838. doi: 10.3389/fonc.2019.00838. eCollection 2019.
3
Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.全脑放疗不能改善 EGFR 突变型 NSCLC 伴软脑膜转移患者的总生存期。
Radiat Oncol. 2019 Sep 14;14(1):168. doi: 10.1186/s13014-019-1376-z.
4
Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.接受劳拉替尼治疗的转移性ALK+肺癌患者神经症状迅速缓解：两例报告
BMJ Case Rep. 2019 Jul 24;12(7):e227299. doi: 10.1136/bcr-2018-227299.
5
Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.免疫检查点抑制剂治疗的非小细胞肺癌伴脑膜转移患者的生存情况。
Eur J Cancer. 2019 Jul;116:182-189. doi: 10.1016/j.ejca.2019.05.019. Epub 2019 Jun 13.
6
Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer.厄洛替尼与贝伐单抗联合治疗EGFR突变型肺癌导致的阿法替尼耐药性软脑膜癌病
Int Cancer Conf J. 2019 Jan 18;8(2):81-85. doi: 10.1007/s13691-019-00358-6. eCollection 2019 Apr.
7
Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.EGFR 酪氨酸激酶抑制剂在难治性脑膜转移 NSCLC 中的活性。
J Thorac Oncol. 2019 Aug;14(8):1400-1407. doi: 10.1016/j.jtho.2019.05.007. Epub 2019 May 18.
8
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.一种针对肺癌脑膜转移患者的特定生存评估的分子分级预后（molGPA）模型。
Lung Cancer. 2019 May;131:134-138. doi: 10.1016/j.lungcan.2019.03.015. Epub 2019 Mar 18.
9
Pemetrexed in the Treatment of Leptomeningeal Metastasis in Patients With EGFR-mutant Lung Cancer.培美曲塞治疗 EGFR 突变型肺癌患者的脑膜转移。
Clin Lung Cancer. 2019 Jul;20(4):e442-e451. doi: 10.1016/j.cllc.2019.03.005. Epub 2019 Mar 29.
10
Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.脑脊液游离 DNA 作为液体活检在 ALK 重排 NSCLC 脑膜转移中的临床应用
J Thorac Oncol. 2019 May;14(5):924-932. doi: 10.1016/j.jtho.2019.01.007. Epub 2019 Jan 17.
Zotero 插件